{"protocolSection": {"identificationModule": {"nctId": "NCT01726049", "orgStudyIdInfo": {"id": "Sildenafil Groningen Study"}, "organization": {"fullName": "University Medical Center Groningen", "class": "OTHER"}, "briefTitle": "Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH", "officialTitle": "Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension"}, "statusModule": {"statusVerifiedDate": "2016-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-10"}, "primaryCompletionDateStruct": {"date": "2014-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-09-21", "studyFirstSubmitQcDate": "2012-11-08", "studyFirstPostDateStruct": {"date": "2012-11-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-16", "resultsFirstSubmitQcDate": "2016-02-20", "resultsFirstPostDateStruct": {"date": "2016-03-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-02-20", "lastUpdatePostDateStruct": {"date": "2016-03-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "E.S. Hoendermis", "investigatorTitle": "MD, PhD", "investigatorAffiliation": "University Medical Center Groningen"}, "leadSponsor": {"name": "University Medical Center Groningen", "class": "OTHER"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) with pulmonary hypertension ( PH).", "detailedDescription": "Rationale: Treatment of diastolic left heart failure is a challenging task. Compared to systolic left heart failure the level of evidence for known medical treatment regiments is low. Sildenafil, a phosphodiesterase 5 (PDE 5) inhibitor and effective therapy for pulmonary arterial hypertension acts as a selective pulmonary vasodilator by inhibiting the impaired nitric oxide (NO) pathway. Reducing the pulmonary vascular resistance would be the primary target by treatment of diastolic left heart failure with PH. But clinical and hemodynamical studies to evaluate the role of Sildenafil in diastolic heart failure, also called heart failure with preserved ejection fraction (HFpEF) with secondary pulmonary hypertension are lacking. Our hypothesis is that Sildenafil decreases pulmonary artery pressure in patients with HFpEF and pulmonary hypertension.\n\nObjective: To investigate whether Sildenafil treatment results in a hemodynamic improvement and in an improvement of exercise capacity in these patients.\n\nStudy design: single-center, prospective, randomized, placebo controlled study. Study population: 52 patients with HFpEF and PH Intervention : One group receives three times daily 20 mg Sildenafil for 2 weeks followed by three times daily 60 mg Sildenafil for 10 weeks. The other group receives three times daily 20 mg of Placebo, followed by 3 times daily 60 mg placebo.\n\nMain study parameters/endpoints:\n\nPrimary objectives\n\n1. To investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure (PAP) in HFpEF patients with PH (investigated invasively by right heart catheterization) .\n\nSecondary objectives\n\n1. To investigate whether Sildenafil treatment results in an reduction of wedge pressure in HFpEF patients.\n2. To investigate whether Sildenafil treatment results in an improvenemt of cardiac output (CO) in HFpEF patients.\n3. To investigate whether Sildenafil treatment results in improvement of exercise capacity in these patients ( defined as change in VO2max)"}, "conditionsModule": {"conditions": ["Heart Failure, Diastolic", "Pulmonary Hypertension"], "keywords": ["HFpEF", "PH"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 52, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sildenafil", "type": "ACTIVE_COMPARATOR", "description": "Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks", "interventionNames": ["Drug: Sildenafil"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Sildenafil", "description": "Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks", "armGroupLabels": ["Sildenafil"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization", "description": "change of mean pulmonary artery pressure between baseline and 12 weeks measured by heart catheterisation", "timeFrame": "baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "VO2max", "description": "difference in change of VO2 max between baseline and 12 weeks between Sildenafil and placebo group", "timeFrame": "baseline and 12 weeks"}, {"measure": "Cardiac Output Measured Invasively by Right Heart Catheterization", "description": "difference in change of cardiac output between baseline and 12 weeks between Sildenafil and Placebo group", "timeFrame": "baseline and 12 weeks"}, {"measure": "Wedge Pressure Measured Invasively by Right Heart Catheterization", "description": "Difference in change of wedge pressure between baseline and 12 weeks between Sildenafil group and Placebo group", "timeFrame": "baseline and 12 weeks"}], "otherOutcomes": [{"measure": "Echocardiographic Parameters of Diastolic LV Dysfunction", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* \\>18 years\n* Written inform consent\n* PH secondary to diastolic left heart failure defined as\n* PAP mean \\>25 mmHg\n* Wedge mean \\>15 mmHg\n* Normal systolic left ventricular (LV) function on echo/nuclear imaging (left ventricular ejection fraction (LVEF) \\> or =45%)\n* New York Heart Association class (NYHA) II-IV despite heart failure therapy\n\nExclusion Criteria:\n\n* Severe noncardiac limitation to exercise (as severe chronic obstructive pulmonary disease)\n* Other cause of PH besides diastolic heart failure\n* Coronary ischemia or recent myocardial infarction (\\<6 months)\n* Hypotension ( \\<90/50 mmHg)\n* Ongoing nitrate therapy\n* Ongoing therapy with citochrome P450 3A4 ( CYP3A4) inhibitors (ketoconazole, erythromycin, cimetidine, clarithromycin, itraconazole, voriconazole and protease inhibitors) or CYP3A4 inductors(carbamacepine, phenytoin, phenobarbital, rifampicin, Sint Janskruid ). Furthermore patients will be informed not to drink grapefruit juice while on study medication because of the known impact of grape fruit on pharmacokinetics of Sildenafil.\n* Ongoing therapy with alpha -inhibitors\n* Significant mitral or aortic valve dysfunction\n* Severe liver dysfunction\n* Pregnancy\n* Unable to read and comprehend Dutch language", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "E S Hoendermis, MD PhD", "affiliation": "University Medical Center Groningen", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University Medical Center Groningen", "city": "Groningen", "zip": "9700 RB", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}]}, "referencesModule": {"references": [{"pmid": "27873388", "type": "DERIVED", "citation": "Liu LC, Hummel YM, van der Meer P, Berger RM, Damman K, van Veldhuisen DJ, Voors AA, Hoendermis ES. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail. 2017 Jan;19(1):116-125. doi: 10.1002/ejhf.662. Epub 2016 Nov 21."}, {"pmid": "26188003", "type": "DERIVED", "citation": "Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015 Oct 7;36(38):2565-73. doi: 10.1093/eurheartj/ehv336. Epub 2015 Jul 17."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Stabile outpatients with heart failure with preserved ejection fraction (HFpEF) and signs of pulmonary hypertension (PH) on echocardiogram were referred for right heart cath as part of clinical care. After heart catheter measurements , eligible patients were asked for participation. Recruitment from october 2011 until september 2014", "groups": [{"id": "FG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "FG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "26"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "refused second HC", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "BG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "52"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72", "spread": "12"}, {"groupId": "BG001", "value": "76", "spread": "7"}, {"groupId": "BG002", "value": "74", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "37"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "52"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization", "description": "change of mean pulmonary artery pressure between baseline and 12 weeks measured by heart catheterisation", "populationDescription": "52 patients randomized. 26 Sildenafil arm: 26 placebo arm: change in mean pulmonary artery pressure could be evaluated in the intention to treat (ITT) analyses in 21 and 22 subjects of the Sildenafil and placebo treatment group", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHG", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.4", "lowerLimit": "-4.5", "upperLimit": "-0.3"}, {"groupId": "OG001", "value": "-4.7", "lowerLimit": "-7.1", "upperLimit": "-2.3"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.5", "ciUpperLimit": "-0.3"}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.1", "ciUpperLimit": "-2.3"}]}, {"type": "SECONDARY", "title": "VO2max", "description": "difference in change of VO2 max between baseline and 12 weeks between Sildenafil and placebo group", "populationDescription": "52 patients randomized. 26 Sildenafil arm: 26 placebo arm: change in VO2max could be evaluated in the ITT analyses in 18 and 22 subjects of the Sildenafil and placebo treatment group", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ml/kg/min", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "lowerLimit": "-0.9", "upperLimit": "1.4"}, {"groupId": "OG001", "value": "0.7", "lowerLimit": "-0.3", "upperLimit": "1.6"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9", "ciUpperLimit": "1.4"}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.3", "ciUpperLimit": "1.6"}]}, {"type": "SECONDARY", "title": "Cardiac Output Measured Invasively by Right Heart Catheterization", "description": "difference in change of cardiac output between baseline and 12 weeks between Sildenafil and Placebo group", "populationDescription": "52 patients randomized. 26 Sildenafil arm: 26 placebo arm: change in cardiac output could be evaluated in the ITT analyses in 20 and 22 subjects of the Sildenafil and placebo treatment group", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mililiter/min", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "lowerLimit": "-0.9", "upperLimit": "0.1"}, {"groupId": "OG001", "value": "-0.2", "lowerLimit": "-0.5", "upperLimit": "0.1"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9", "ciUpperLimit": "0.1"}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5", "ciUpperLimit": "0.1"}]}, {"type": "SECONDARY", "title": "Wedge Pressure Measured Invasively by Right Heart Catheterization", "description": "Difference in change of wedge pressure between baseline and 12 weeks between Sildenafil group and Placebo group", "populationDescription": "52 patients randomized. 26 Sildenafil arm: 26 placebo arm: change in wedge pressure could be evaluated in the ITT analyses in 21 and 22 subjects of the Sildenafil and placebo treatment group", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "lowerLimit": "-1.9", "upperLimit": "1.0"}, {"groupId": "OG001", "value": "-3.5", "lowerLimit": "-5.2", "upperLimit": "-1.8"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.9", "ciUpperLimit": "1.0"}, {"groupIds": ["OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.2", "ciUpperLimit": "-1.8"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Echocardiographic Parameters of Diastolic LV Dysfunction", "reportingStatus": "NOT_POSTED", "timeFrame": "12 weeks"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "3 months", "eventGroups": [{"id": "EG000", "title": "Sildenafil", "description": "Sildenafil: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks", "seriousNumAffected": 4, "seriousNumAtRisk": 26, "otherNumAffected": 22, "otherNumAtRisk": 26}, {"id": "EG001", "title": "Placebo", "description": "Placebo: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 26, "otherNumAffected": 21, "otherNumAtRisk": 26}], "seriousEvents": [{"term": "intestinal infarction", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 26}]}, {"term": "cardiac failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}]}, {"term": "pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 26}]}, {"term": "pseudoaneurysma", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}]}, {"term": "medical device complication", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 26}]}], "otherEvents": [{"term": "headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 26}]}, {"term": "dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}]}, {"term": "visual impairment", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 26}]}, {"term": "myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 26}]}, {"term": "respiratory tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 26}]}, {"term": "chest pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 26}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "E.S. Hoendermis, MD, PHD", "organization": "University Hospital Groningen, NL", "email": "e.s.hoendermis@umcg.nl", "phone": "0031503616161"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000006973", "term": "Hypertension"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "asFound": "Pulmonary Hypertension", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Heart Failure, Diastolic", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068677", "term": "Sildenafil Citrate"}], "ancestors": [{"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058986", "term": "Phosphodiesterase 5 Inhibitors"}, {"id": "D000010726", "term": "Phosphodiesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000064804", "term": "Urological Agents"}], "browseLeaves": [{"id": "M292", "name": "Sildenafil Citrate", "asFound": "Memory", "relevance": "HIGH"}, {"id": "M21320", "name": "Citric Acid", "relevance": "LOW"}, {"id": "M1837", "name": "Sodium Citrate", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29332", "name": "Phosphodiesterase 5 Inhibitors", "relevance": "LOW"}, {"id": "M13629", "name": "Phosphodiesterase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "T382", "name": "Citrate", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Urol", "name": "Urological Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnCoag", "name": "Anticoagulants"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}